AWS credits for biotech startups — the $75K–$200K paths that fund GxP-aligned drug discovery infrastructure.

IWhy biotech credit pools sit at the top of the non-AI vertical band

A biotech startup running computational discovery is not a general-purpose B2B SaaS company from AWS's perspective, and it is not a healthtech app either. The workload profile combines two characteristics that each push the credit ceiling up: GPU-heavy batch compute that consumes meaningful AWS revenue per workload, and multi-jurisdictional compliance architecture that consumes meaningful partner labor. The combination puts biotech at the top of the non-AI credit band, with realistic pools at $75K–$200K depending on stage and use case.

The first driver is the computational footprint. A biotech doing structure prediction with AlphaFold-derived workflows, molecular dynamics with GROMACS or AMBER, or de novo design with SageMaker-hosted custom models burns AWS in spikes that look more like an AI training shop than a SaaS application. A single virtual-screening campaign across a 10M-compound library can consume 50,000–200,000 EC2 vCPU-hours over a weekend. A molecular dynamics ensemble for a single target can consume 8,000–20,000 GPU-hours on ml.p4d instances. AWS recognizes the consumption curve and the credit ceiling tracks the projected spend.

The second driver is the compliance labor. A biotech operating under GxP — Good Manufacturing Practice for any cell-line or compound production work, Good Laboratory Practice for preclinical safety studies, Good Clinical Practice for human-subject trials — has a documented infrastructure-validation obligation. The FDA enforces 21 CFR Part 11 for electronic records and signatures in regulated workflows. The EMA enforces Annex 11. The PMDA enforces equivalents in Japan. Each regime expects auditable evidence: who changed what, when, with what authorization, and how the change was tested before promotion to production. The AWS architecture that produces that evidence is the substrate the Build for Startups credit funds.

The third driver is the partnership shape. Biotech credit applications frequently arrive with a contracted compute deadline attached — an IND filing scheduled, a Phase 1 trial starting, a pharma collaboration with a milestone payment tied to a computational deliverable. AWS reviewers see the use-case narrative cite the milestone and fast-track the approval because the credit pool is funding contractually-committed AWS workloads with hard go-live dates. Approval times compress; downgrade rates fall.

The numerical implication: a general B2B SaaS Series-A typically lands $100K in Activate Portfolio credits. A biotech Series-A with the same funding profile typically lands $100K Portfolio + $25K Build for Startups for the GxP audit-substrate work + $25K–$50K Bedrock POC if there is a literature-summarization or regulatory-writing workload on the roadmap. The total credit pool routinely reaches $150K–$175K for Series-A biotech; pre-IND companies with a more developed computational program can push toward $200K when the projected AWS consumption justifies the higher Portfolio tier.

A second-order point that often matters more than founders expect: the partner labor delta is real. A GxP-aligned AWS account takes the partner roughly 60–120 engineer-hours more than a non-regulated equivalent — multi-account topology with validated promotion workflows, KMS key management with documented rotation, CloudTrail across the AWS Organizations setup with tamper evidence, S3 Object Lock configurations for raw experimental data, computer system validation (CSV) documentation that maps controls to 21 CFR Part 11 sub-clauses. That delta is the budget the partner uses to file the Build for Startups track on the customer's behalf. If the partner is not asking for it, the budget goes unspent and the customer loses $25K of stackable credit.

IIGxP and 21 CFR Part 11: what the partner-filed architecture actually delivers

GxP is the umbrella term for the Good Practice regulations the FDA, EMA, and PMDA enforce across the drug-development lifecycle. The relevant ones for biotech infrastructure decisions are GMP (manufacturing), GLP (preclinical safety studies), and GCP (clinical trials). Each carries computer-system requirements that AWS satisfies at the infrastructure level only when the architecture is configured to do so. The partner-filed Build for Startups engagement is the mechanism that delivers the configuration.

AWS publishes a GxP whitepaper that maps AWS services to GxP control expectations and 21 CFR Part 11 sub-clauses. The whitepaper does not certify the customer as GxP-compliant — it provides the shared-responsibility map. AWS handles the infrastructure controls (physical security, hypervisor isolation, region availability); the customer handles the application controls (user authentication, electronic-signature workflows, change-management documentation, retention policies). The partner-filed engagement bridges the two by configuring AWS services so the customer's controls inherit from auditable AWS evidence.

21 CFR Part 11 has two practical surfaces an AWS architecture must address. The first is electronic records — any record the FDA expects to inspect (raw assay data, analytical results, batch records, validation documentation) must be stored with integrity controls, time-stamped capture, and auditable change history. The second is electronic signatures — any approval workflow that would be wet-signed in a paper system (batch release, protocol amendment, deviation closeout) must be implemented with authenticated identity, intent-of-signing capture, and tamper-evident binding to the signed record. The CloudTrail + KMS + S3 Object Lock stack delivers the records surface; the IAM + Cognito + EventBridge stack delivers the signatures surface; the validation documentation that maps both to 21 CFR Part 11.10 sub-clauses is the deliverable that closes the audit-readiness gap.

The partner work on the records surface typically includes: CloudTrail enabled across every account in the AWS Organizations setup with log file integrity validation turned on; trail logs shipped to a dedicated logging account in S3 with KMS-encrypted storage and bucket policies that prevent log deletion; S3 Object Lock configured in compliance mode for raw experimental data and regulatory submission archives, with retention periods that match the longest applicable GxP retention requirement (typically 25 years for clinical trial records under FDA expectations); KMS customer-managed keys with documented rotation policies and access-logging enabled on every key used for record encryption; AWS Config rules that detect drift from the validated baseline and emit events when the GxP-relevant configuration changes.

The partner work on the signatures surface typically includes: IAM federation that maps signing identities to authenticated corporate accounts (not shared service accounts); Cognito-backed signature capture flows for end-user signing events with intent-of-signing prompts ("I, [authenticated user], approve this batch release"); EventBridge rules that emit signed-event records to the immutable log substrate; and the application-layer logic that binds each signature to the specific record version being signed via a cryptographic hash.

The validation documentation — computer system validation, or CSV — is the deliverable that an FDA Form 483 inspector or an EMA GxP auditor asks for. The partner-filed engagement produces a validation package that includes the system architecture diagram, the data-flow diagram showing record creation through retention, the IQ/OQ/PQ test scripts (installation, operational, and performance qualification), the user-acceptance test results, the deviation log, and the change-control runbook that governs how future changes are tested before promotion. This documentation is the partner deliverable that takes the most labor and is the primary thing the Build for Startups credit pays for.

IIISpot Instances, Capacity Reservations, and HealthOmics for batch computational workloads

Biotech computational workloads are batch-shaped and embarrassingly parallel. Virtual screening, docking, molecular dynamics ensembles, free-energy perturbation calculations, and genomics pipelines all decompose into thousands or millions of independent tasks. The credit math on these workloads turns on two AWS-specific levers: Spot Instances for cost-optimized batch consumption, and EC2 Capacity Reservations or AWS HealthOmics for predictable capacity when the workload has a deadline.

Spot Instances are spare EC2 capacity AWS offers at a discount of 70–90% off on-demand pricing in exchange for the right to reclaim the instance with a two-minute warning. For embarrassingly parallel biotech workloads with checkpointing, the reclaim risk is manageable — a reclaimed task restarts from the last checkpoint on a different instance, and the wall-clock loss is minutes per reclaim event. CloudRoute partners report that biotech batch workloads with proper checkpointing routinely capture 70–90%+ of total compute as Spot, which extends the credit pool 3–4x compared to running the same workload on-demand. A $100K Portfolio award that would fund 4 months of on-demand consumption funds 12–16 months when 80% Spot capture is achieved.

Capacity Reservations are the complement for the predictable-deadline portion of the workload. When a biotech has a contracted compute deliverable — a CRO engagement that requires a specific number of GROMACS-hours by a specific date, a pharma collaboration with a virtual-screening campaign tied to a milestone payment, a Phase 1 readout that requires PK/PD modeling by the data-cut deadline — running the deadline-bound portion on Capacity Reservations or Reserved Instances guarantees the compute is available when the workload is scheduled. The credit pool funds both: the Spot-heavy speculative discovery work, and the reservation-protected deadline-bound work.

AWS HealthOmics is the genomics-specific managed service that biotech credit applications consistently reference. HealthOmics provides managed storage for sequencing data (reference, sequence, and variant stores), managed workflow execution for tertiary analysis (Nextflow, WDL, CWL-defined pipelines), and managed annotation services. Storage in HealthOmics sequence stores is roughly 50% cheaper than equivalent S3 storage for raw FASTQ data at scale because the service is optimized for the genomics access patterns, and the storage-tiered cold archive is integrated into the same workflow surface. Partner-filed Portfolio applications for biotech doing genomics work consistently include HealthOmics line items in the projected spend breakdown.

The partner-filed architecture typically arranges these layers as a hierarchy. The speculative discovery layer runs on Spot through AWS Batch or SageMaker Training Jobs, capturing 80%+ of total compute as Spot. The deadline-bound production layer runs on Capacity Reservations or HealthOmics managed workflows with guaranteed availability. The validation-regulated layer runs on a dedicated GxP-validated account with full audit logging and Object Lock storage. Each layer has its own credit-pool allocation; the credit application articulates the three workloads as distinct but stackable consumption surfaces.

IVSageMaker for de novo design, target identification, and ADMET prediction

In silico drug discovery has shifted heavily toward ML-driven approaches over the past five years. De novo molecular design with generative models, target identification with graph neural networks, ADMET prediction with transformer-based property predictors, and structure-aware binding affinity prediction with geometric deep learning are all routinely run as SageMaker training and inference workloads in 2026. The credit pool allocation between training and inference matters because the two pools draw from different sub-tracks.

SageMaker Training Jobs are the primary mechanism for ML-driven discovery work at biotech startups. A typical Series-A biotech doing target identification might fine-tune a graph neural network on a proprietary target-interaction dataset, with training runs consuming $3K–$10K per run and 30–80 runs over an experimentation cycle. A biotech doing de novo design might train a generative model — a transformer-decoder over SMILES or SELFIES, a diffusion model over molecular conformations, a flow-matching model over 3D structures — with training runs consuming $8K–$30K per run on 16x A100 or 8x H100 clusters. The training surface is what Activate Portfolio funds; the workload-specific buildout (a new model architecture, a new evaluation harness, a new property predictor for a new endpoint) is what Build for Startups funds when scoped as a distinct workload.

SageMaker inference endpoints are the production-facing surface for discovery work. ADMET predictors for the in silico screening cascade, retrosynthesis predictors for synthetic accessibility scoring, structure predictors for batch protein-structure annotation — all routinely deployed as managed endpoints that the discovery pipeline calls programmatically. Endpoint costs typically run $500–$3,000/month per active endpoint depending on instance type and traffic. Activate Portfolio funds these; there is no Bedrock-equivalent POC pool for SageMaker custom-model inference, which is one of the structural quirks biotech CTOs should know when planning the application.

The split between training-compute consumption and inference-compute consumption changes the credit-pool composition. A biotech in the active model-development phase — building a new generative model from scratch, fine-tuning a foundation model on a proprietary dataset, running large-scale hyperparameter sweeps — has training-heavy consumption that pushes Portfolio toward the $100K ceiling. A biotech in the production-deployment phase — operating an established pipeline of ADMET predictors, running batch inference against new compound libraries — has inference-heavy consumption that runs cooler per workload but accumulates over time. Partner-filed applications articulate the phase in the use-case narrative; AWS reviewers approve Portfolio at the ceiling when the projected training spend matches the workload description.

A practical pattern that approves at the top of the band: a biotech with both a training program (de novo design or target identification) and a production inference pipeline (ADMET cascade) files Portfolio for the broad infrastructure, Build for Startups for the GxP audit substrate, and Bedrock POC for an adjacent literature-summarization or regulatory-writing workload. The three pools stack cleanly because each maps to a distinct workload: Portfolio funds the SageMaker discovery infrastructure, Build for Startups funds the audit substrate around the regulated boundary, and Bedrock POC funds the foundation-model-driven adjacent workload. The total reaches $150K reliably and $175K when the Bedrock POC scope justifies the higher award tier.

VBedrock POC funding for biotech: literature summarization, protocol generation, regulatory writing

Foundation models are not the primary discovery tool in biotech — that role belongs to specialized SageMaker workloads on chemistry- and biology-aware architectures. But foundation models have become genuinely useful for the writing-heavy and reading-heavy work that surrounds discovery: scientific literature summarization, assay protocol generation, regulatory writing assistance, and the synthesis of large-text corpora into structured artifacts. The Bedrock POC track funds these workloads at $10K–$50K per POC when the scope is documented.

The Bedrock-eligible use cases that approve at biotech credit applications in 2026:

• Scientific literature summarization — synthesizing the published literature on a target, indication, or mechanism into structured briefs for internal use. The PubMed corpus, biorxiv, medrxiv, and licensed full-text databases are typically the inputs; the model produces structured outputs (target evidence summaries, mechanism reviews, competitive landscape briefs). Claude Opus performs noticeably better than smaller models on these tasks because the reasoning required to weight conflicting evidence across studies benefits from the larger model. Typical award: $25K–$50K because Opus inference is expensive per call and the use-case value justifies the spend.
• Assay protocol generation — drafting standard operating procedures for laboratory assays from a high-level description plus reference protocols. The protocol surface is procedural — list of materials, stepwise method, acceptance criteria, troubleshooting notes — which foundation models handle reliably when grounded in reference documents through RAG. Typical award: $10K–$25K.
• Regulatory writing assistance — drafting investigator brochure sections, clinical trial protocols, IND module narratives, and CMC sections from internal source documents. The work product is heavily structured (eCTD module shapes, ICH guideline sections) and the foundation model accelerates the first-draft turnaround. Typical award: $25K because the inference volume is moderate but the workflow value is high.
• Compound search and natural-language chemistry queries — conversational front-ends over internal compound databases, returning structured results for chemist queries ("show me all compounds tested against [target] with IC50 below 1 micromolar and CYP3A4 inhibition below threshold"). The PHI-equivalent surface is internal proprietary data, not regulated patient data, but the architecture pattern is similar. Typical award: $10K–$25K.
• Lab-notebook summarization and knowledge extraction — extracting structured information from electronic lab notebook entries, free-text experimental observations, and internal communications into a knowledge graph or structured database. Typical award: $10K–$25K.

The biotech-specific element of the POC plan is the data-handling section. Foundation-model inputs from a biotech operation may include proprietary chemical structures, target identification leads, target validation data, mechanistic hypotheses, and (where clinical) patient data. The POC plan should specify the data classification (proprietary, regulated, clinical), the residency requirement (US, EU, or APAC), the model selection rationale (Opus for high-stakes reasoning, Sonnet for general use, Haiku for high-volume routing), and the eval methodology — Cohen's kappa against expert review for classification, ROUGE or domain-expert rating for generation, factual-accuracy auditing against reference for summarization. Vague POC plans approve at the floor ($10K); well-scoped plans approve at the middle of the range ($25K) or higher.

The Bedrock POC credits are Bedrock-earmarked: they fund Bedrock inference, the OpenSearch instance for vector search in RAG workflows, the S3 storage for prompt logs and embedded reference documents, and the Lambda orchestration glue. They cannot fund unrelated SageMaker training jobs or EC2 batch compute. This is the same constraint as non-biotech Bedrock POCs; biotech specificity changes the use cases but not the spending rules.

VIClinical trial milestones and the timing of the credit application

A pattern in the routed-engagement data: roughly 60% of biotech credit applications are filed against an upcoming clinical-trial milestone or a contracted pharma-partnership deliverable. The milestone drives the AWS-architecture deadline, the architecture deadline drives the credit application, and the credit application drives the partner engagement. The earlier in the cycle the application starts, the more architecture work fits inside the runway.

IND filings are the most common driver for early-stage biotech credit applications. An IND submission packet includes the nonclinical pharmacology and toxicology summary, the CMC section, the proposed Phase 1 protocol, and the investigator brochure — all of which are produced through workflows that touch the AWS environment in some way (data analysis, document generation, raw-data archival, electronic submission preparation). The FDA expects the supporting raw data to be available for inspection on request; the partner-filed architecture work ensures the raw data is archived with 21 CFR Part 11–aligned controls and retrievable on inspection demand.

Phase 1 and Phase 2 trial starts are the second category of timing drivers. The clinical-data-management workflow — eCRF design, EDC integration, central lab data ingestion, monitoring dashboards, statistical analysis pipelines — runs on AWS for most modern biotech operations. The trial-start date sets the go-live deadline for the data-management substrate. CloudRoute partners report that 60-day trial-start deadlines collapse the architecture window to the point where some work has to push to the post-go-live period; 90-day deadlines are workable; 120-day deadlines allow the full GxP-aligned buildout to complete pre-go-live.

Pharma-partnership deliverables are the third category. A contracted milestone payment with a computational deliverable date — a virtual screening campaign delivered to the partner by a specific date, a target identification analysis delivered to the partner by a specific date — drives the credit application because the milestone payment depends on the deliverable, and the deliverable depends on the AWS environment being production-ready. The credit application narrative cites the partnership and the milestone date; AWS reviewers fast-track applications with contracted delivery dates because the credit pool is funding contractually-committed AWS workloads.

The timing math: from inquiry to credits-in-account is 12–20 days under standard CloudRoute routing for biotech (slightly longer than the 11–18 days for healthtech because the biotech application paperwork carries more compliance documentation). From inquiry to a production GxP-aligned AWS environment is typically 8–12 weeks if the partner starts work as soon as credits are approved. That leaves a comfortable buffer for a 120-day clinical trial deadline and a tight-but-workable timeline for a 90-day deadline. Below 60 days, the architecture work has to be staged — non-regulated workloads come up first, the regulated boundary comes up second, and CSV documentation closes out in the final weeks.

A common failure mode: the founder waits until 45 days before the IND filing or trial start to begin the credit conversation. The partner can usually still land credits in 14–18 days, but the GxP-aligned architecture work and the validation documentation cannot be completed in the remaining 27–31 days. The trial launches with the regulated workload on a partially-validated environment under a temporary validation deviation, the CRO's QA team flags the deviation, and the trial start stalls while the documentation is completed under deadline pressure. The fix is to start the credit + partner conversation at 90+ days from the milestone, not 45.

VIICross-border data residency: US, EU, and APAC clinical data on AWS

Biotech operations that span multiple regulatory jurisdictions face an AWS-region-selection problem that healthtech operations typically do not. A biotech running a Phase 2 trial with sites in the US, the EU, and Japan generates clinical data that has residency expectations in each jurisdiction. The AWS architecture has to accommodate multi-region replication while satisfying GDPR in the EU, the Act on the Protection of Personal Information (APPI) in Japan, and HIPAA in the US where clinical data crosses the patient-identifiability threshold.

For US-only clinical trials, the residency story is simple: us-east-1 (N. Virginia), us-east-2 (Ohio), us-west-2 (Oregon), and the AWS GovCloud regions for federally-regulated workloads. HIPAA-eligible services apply where clinical data is patient-identifiable; the BAA mechanics are equivalent to the healthtech case. The partner-filed architecture work for US-only biotech tracks closely with the healthtech architecture template.

For EU clinical trials, the residency expectation is that EU-resident patient data stays in EU regions. The Frankfurt (eu-central-1), Ireland (eu-west-1), Paris (eu-west-3), and Stockholm (eu-north-1) regions are the common choices. GDPR's data-protection rules apply directly; member-state additions vary (Germany's BDSG, France's data protection act, Italy's data protection authority guidance). The partner-filed architecture typically includes region-specific account topology with EU clinical data confined to EU regions and US-side analysis access mediated through controlled cross-region read endpoints.

For Japanese clinical trials and PMDA-regulated workloads, the Tokyo (ap-northeast-1) and Osaka (ap-northeast-3) regions are the common choices. The APPI carries data-handling expectations broadly aligned with GDPR. PMDA's expectations on computer-system validation for clinical data systems mirror FDA 21 CFR Part 11 in their substantive controls. Partner-filed engagements for biotech with PMDA exposure include the region-selection analysis and the validation documentation mapping to the PMDA framework.

The cross-region replication architecture is what the credit pool funds for multi-region biotech. The partner work typically includes: per-region account topology with regulated workloads confined to the appropriate region; cross-region replication of de-identified analytical data sets through controlled S3 replication policies; centralized identity and access management through AWS IAM Identity Center with region-aware permissions; centralized audit logging that aggregates CloudTrail and Config events from all regions into a single inspection surface for global compliance review; and the per-jurisdiction CSV documentation that maps regional controls to the appropriate regulatory framework. The partner labor on this multi-region work is the reason cross-border biotech credit pools commonly land at the top of the band ($175K–$200K) rather than the middle.

A practical sequencing note: when the biotech operation will eventually span multiple regions but the initial workload is single-region, the partner-filed architecture builds the multi-account topology and the region-aware audit substrate at engagement start, even when only one region is initially populated. Retrofitting region-aware topology to a single-region account that has accumulated regulated data is meaningfully more expensive than building it upfront. The credit pool covers the upfront work either way; the cost asymmetry is in the rework.

VIIIEvery credit track for biotech startups — side by side

IXWhat the next 20 days look like for a biotech inquiry

A biotech-specific timeline pulled from CloudRoute's routed-engagement data. Numbers shift ±4 days based on whether the GxP scope is single-jurisdiction or cross-border, whether the AWS account already exists, and whether the partner has prior biotech engagements with the relevant compliance regime.

Day 0 — You submit an inquiry to CloudRoute (3 minutes). The form asks two biotech-specific questions: is there a clinical-trial milestone or a contracted pharma deliverable driving the deadline, and what is the geographic scope of the workload? We use both to bias routing toward partners with the relevant compliance and regional experience.

Day 1 — Routed to a partner with GxP architecture experience and (where applicable) cross-border clinical-data delivery experience. You receive a Calendly link.

Day 2–4 — 30- to 45-minute discovery call. Partner confirms the GxP scope (GMP/GLP/GCP, 21 CFR Part 11 surface), the computational workload (SageMaker discovery, Batch screening, HealthOmics genomics), the regulatory milestone driving the deadline, the multi-region exposure, and the credit-track scope (Portfolio + Build for Startups + Bedrock POC if applicable). They share the application worksheet.

Day 4–6 — You fill in the worksheet — company info, AWS account ID, milestone deadline, projected AWS spend across the compute layers, the use-case paragraph the partner pre-drafts for you. ~45 minutes of founder time because the biotech worksheet captures more compliance context than the healthtech version.

Day 5–7 — Partner files the ACE records: Portfolio (broad infrastructure including SageMaker, Batch, HealthOmics), Build for Startups (GxP audit substrate and CSV documentation), Bedrock POC (literature summarization or regulatory writing if applicable). Filing all three in the same week is standard.

Day 9–14 — AWS reviewer queue processes the records. Clinical-trial-cited and pharma-partnership-cited applications fast-track at the front of this window.

Day 14–18 — Credits land in your AWS billing console under "Promotional credits." Portfolio credits are general-purpose; Bedrock POC credits are Bedrock-earmarked; Build for Startups credits are tagged to the GxP audit substrate workload.

Day 18–20 — Partner kicks off the architecture work. Account topology is set up first (multi-account with regulated/non-regulated separation, multi-region if applicable), then encryption and key-management posture (KMS customer-managed keys with documented rotation), then audit substrate (CloudTrail across accounts and regions with tamper evidence, S3 Object Lock for regulated record archives), then the computational layer (Batch job queues with Spot fleet diversification, SageMaker pipelines, HealthOmics workflows where applicable).

Week 4–10 — Production AWS environment converges on the GxP-aligned target architecture. CSV documentation is delivered as part of the engagement, mapping each architectural control to the relevant 21 CFR Part 11 or Annex 11 sub-clause. Clinical trial start or IND filing or pharma deliverable lands on the production environment.

XThe five mistakes biotech founders make on credit applications

Mistake 1: Underestimating the Spot-vs-on-demand multiplier. Biotech batch workloads — virtual screening, molecular dynamics, structure prediction at scale — can capture 70–90%+ as Spot with proper checkpointing. The credit-runway difference is meaningful: a $100K Portfolio award funds 4 months on-demand or 14+ months at 80% Spot capture. Founders sometimes scope the credit application against on-demand projected spend and then find the credit pool exhausting faster than expected because the architecture is not Spot-first. The partner-filed engagement should set up Spot-first by default; if it does not, ask why.

Mistake 2: Conflating GxP and HIPAA. The two regimes overlap where clinical biotech operations exist, but they are not the same. HIPAA covers patient-identifiable health information; GxP covers regulated activities across the drug-development lifecycle including preclinical work that has no patient data. A preclinical-stage biotech doing in silico discovery work has GxP/Part 11 exposure (any data going into an IND submission) but typically no HIPAA exposure. The architecture work is different: GxP/Part 11 emphasizes immutable records and validation documentation; HIPAA emphasizes encryption-at-rest and access controls. The partner-filed engagement should articulate which regime applies to which workload.

Mistake 3: Skipping the Build for Startups track for GxP work. The GxP audit substrate is the canonical distinct workload for biotech Build for Startups filings — CloudTrail tamper evidence, S3 Object Lock for regulated archives, validated change-control workflows, CSV documentation. AWS reviewers approve this at $25K consistently because the work is structurally separable from general infrastructure. Biotech applications that file only Portfolio leave the $25K on the table.

Mistake 4: Filing a Bedrock POC for a vague scientific-AI idea. "We are exploring AI for literature search" approves at the floor ($10K) if it approves at all. "We are building a target-evidence-synthesis workflow on Claude Opus, evaluating against N=200 expert-rated target briefs with a target accuracy threshold of 85% on factual claims, with a 60-day POC window and $12K/month projected Bedrock spend across Opus and Sonnet inference for the cascade" approves at $25K–$50K. The specificity of the POC plan determines the credit award.

Mistake 5: Starting the credit conversation 45 days before the milestone. Credits land in 14–18 days; GxP-aligned architecture work and CSV documentation take 6–10 weeks. A 45-day timeline collapses the architecture window to 27–31 days, which is not enough to deliver the validated production target. Trial starts or IND filings under partial validation are workable but trigger compliance deviations that have to be remediated under deadline pressure. Start the credit + partner conversation at 90+ days from the milestone to give the validated architecture work the runway it needs.